Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2006-03-14
2006-03-14
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S134100, C424S141100, C424S142100, C424S143100, C424S144100, C514S012200, C514S021800, C530S387300, C530S388100, C530S388150, C530S388220, C530S388750, C530S350000
Reexamination Certificate
active
07011833
ABSTRACT:
Methods of enhancing immune responses in which soluble forms of costimulatory molecules, e.g., B7 molecules, are administered to augment immune responses to antigens, e.g., to tumor cells and infectious agents are provided. The subject methods are useful for both prophylactic and therapeutic immunization of subjects.
REFERENCES:
patent: 5116964 (1992-05-01), Capon et al.
patent: 5434131 (1995-07-01), Linsley et al.
patent: 5580756 (1996-12-01), Linsley et al.
patent: 5686281 (1997-11-01), Roberts
patent: 5712149 (1998-01-01), Roberts
patent: 5738852 (1998-04-01), Robinson et al.
patent: 6071716 (2000-06-01), Freeman et al.
patent: 6130316 (2000-10-01), Freeman et al.
patent: 6149905 (2000-11-01), Ostrand-Rosenberg et al.
patent: WO 95/06738 (1995-05-01), None
patent: WO 97/38711 (1997-10-01), None
patent: WO 00/06605 (2000-02-01), None
Grewal and Flavell Annu. Rev. Immunol 1998; 16: 111-135.
Coyle and Gutierrez-Ramos, Nature Immunol. 2001;2:203-209.
Dunussi-Joannopoulos et al. Blood 1998, 96:617A.
Chen, A. et al., “Non-glycosylated human B7-1(CD80) retains the capacity to bind its counter-receptors,”FEBS Lett.May 29, 1998;428(3):127-34.
Corry, D.B. et al., “Differential effects of blockade of CD28-B7 on the development of Th 1 or Th2 effector cells in experimental leishmaniasis,”J. Immunol., Nov. 1, 1994;153(9):4142-8.
Dellabona, P. et al., “Possible Use of Soluble Co-Stimulatory Molecules to Trigger Anti Tmour Immune Response In Vivo,”J. Cellular Biochemistry Suppl., Feb. 26-Apr. 17, 1994;18D:426.
Fields, P.E. et al., “B7.1 is a quantitatively stronger costimulus than B7.2 in the activation of naive CD8+ TCR-transgenic T cells,”J. Immunol., Nov. 15, 1998;161(10):5268-75.
Freeman, G.J. et al., “B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4,”Immunity, May 1995;2(5):523-32.
Harding, F.A. et al., “CD28-B7 interactions allow the induction of CD8+ cytotoxic T lymphocytes in the absence of exogenous help,”J. Exp. Med., Jun. 1, 1993;177(6):1791-6.
Kuchroo, V.K. et al. “B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy,”Cell, Mar. 10, 1995;80(5):707-18.
Lenschow, D.J. et al., “Differential effects of anti-B7-1 and anti B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse,”J. Exp. Med., Mar. 1, 1995;181(3):1145-55.
McAdam, A.J. et al., The role of B7 co-stimulation in activation and differentiation of CD4+ and CD8+ T cells,Immunol. Rev., Oct. 1998;165:231-47.
Moro, M. et al., “Induction of therapeutic T-cell immunity by tumor targeting with soluble recombinant B7-immunoglobulin costimulatory molecules,”Cancer Res.Jun. 1, 1999;59(11):2650-6.
Rao, J.B. et al., “IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression,”J. Immunol.May 1, 1996;156(9):3357-65.
Rennert, P. et al., “The IgV domain of human B7-2 (CD86) is sufficient to co-stimulate T lymphocytes and induce cytokine secretion,”Int. Immunol.Jun. 1997;9(6):805-13.
Rulifson, I.C. et al., “CD28 costimulation promotes the production of Th2 cytokines,”J. Immunol., Jan. 15, 1997;158(2):658-65.
Schweitzer, A.N. et al., “Role of costimulators in T cell differentiation: studies using antigen-presenting cells lacking expression of CD80 or CD86,”J. Immunol., Mar. 15, 1997;158(6):2713-22.
O'Toole Margot
Sturmhoefel Knut
Wolf Stanley F.
Gambel Phillip
Genetics Institute Inc.
Kanik Cynthia L.
Mandragouras Amy E.
Ouspenski Ilia
LandOfFree
Enhancing immune responses with B7-1 or B7-2 in the absence... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Enhancing immune responses with B7-1 or B7-2 in the absence..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enhancing immune responses with B7-1 or B7-2 in the absence... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3555762